Dass CR, Choong PF (2006) Biophysical delivery of peptides: applicability for cancer therapy
Evidence snapshot: The strongest available evidence is a small Phase 1 human trial (Teichman et al., 2006) showing dose-dependent, sustained elevation of GH and IGF-1 in healthy adults
Among those who stayed on treatment for the full 68 weeks, cagrilintide 2.4 mg delivered an average of about 12% body weight reduction , compared to 2.3% for placebo
Pradhan L, Nabzdyk C, Andersen ND, LoGerfo FW, Veves A (2009) Inflammation and neuropeptides: the connection in diabetic wound healing
Self-prescribing B12 injections for weight loss purposes is not supported by clinical evidence and may delay diagnosis of underlying conditions contributing to weight concerns or low energy levels